

## Erratum

In the paper by Pouleur *et al.*,<sup>1</sup> the affiliation for Fausto Pinto was given incorrectly. The correct affiliation is <sup>7</sup>Department of Cardiology, CHLN, CCUL (Cardiovascular Centre), AIDFM, Hospital de Santa Maria, Universidade de Lisboa, Lisbon, Portugal.

The publishers apologize for the error.

## Reference

1. Pouleur A-C, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, Lhommel R, Mahmud M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu J-N, Van Overstraeten N, Wachter R, Balligand J-L. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). *ESC Heart Fail* 2018; 5: 830–841.